Current hormonal therapies targeting oestrogen receptor (ERα) activity have been effectively used to treat ERα positive (ERα+) Luminal A and Luminal B breast cancers, which account for ~ 70% of diagnoses [5]. Here, ESR1 is linked to breast cancer.